To access this element change to forms mode OFF
Grant Award View - GA217912
Eliminating HIV that persists on antiretroviral therapy through...
GA ID:
GA217912
Agency:
Department of Health and Aged Care
Approval Date:
6-Dec-2021
Publish Date:
16-Feb-2022
Category:
Health and Medical Research
Grant Term:
1-Feb-2022 to 31-Jan-2025
Value (AUD):
$1,400,752.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 21/22 1.1 Health Policy Research and Analysis
Grant Program:
MRFF Research Grants
Grant Activity:
Eliminating HIV that persists on antiretroviral therapy through treatment with the BCL-2 antagonist, venetoclax
Purpose:
The main barrier to curing HIV is persistence of the virus in a latent for in long-lived cells. This is partly driven be changed in cell death pathways, which can be targeted with venetoclax, a drug recently approved for cancer treatment. We aim to establish safety of venetoclax in people living with HIV without cancer and determine whether venetoclax can eliminate HIV infected cells. This will clarify whether venetoclax may contribute to a safe and effective cure for HIV.
GO ID:
GO Title:
MRFF 2021 Rare Cancers Rare Diseases Unmet Need General - Grant Opportunity
Internal Reference ID:
2021/MRF2015299
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA